The AstraZeneca oral RORgt inverse agonist, AZD0284 , is an inverse agonist of the nuclear receptor RORC2 (RORγt). Reviewer Chris Gampe says, “targeting the activation and function of Th17 cells has been successful for the treatment of autoimmune disease (cf. IL-17, IL-17R, IL-23 Abs). RORC2 is the transcription factor that controls Th17 [...]
< 1 minute read
Oct. 6, 2021
AZD0284: An Oral RORgt Inverse Agonist
AZD0284
oral RORC2 inverse agonist for psoriasis 100 mg PO BID, Ph. I term. due to preclin. Data from opt. of lit. inverse agonist Journal of Medicinal Chemistry AstraZeneca, Gothenburg, Sweden
Loading...
